PUBLISHER: Grand View Research | PRODUCT CODE: 1726176
PUBLISHER: Grand View Research | PRODUCT CODE: 1726176
The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.
The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.
Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.
The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.
U.S. Interventional Oncology Market Report Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use: